R&D News | pharmaphorum

News

"Tokyo, Japan - May 11, 2012: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849."

Pfizer prepares to file COVID-19 shot after reaching safety ...

Pfizer is preparing to file its COVID-19 vaccine after a trial reached the safety milestone required by US regulators for emergency use, according to press reports.

News

Lead Pharma signs $308m immune drug deal with Roche

Lead Pharma has signed a potential 260 million euro ($308 million) deal with Roche to develop small molecule drugs for immune diseases.

News

Could an antidepressant be used to treat COVID-19?

The antidepressant fluvoxamine merits further investigation as a potential treatment for COVID-19 according to findings of a preliminary trial.

News

UK eyes access deal as Moderna’s COVID-19 shot hits the mark

Moderna is the third group in a week to report encouraging phase 3 data with a coronavirus vaccine, saying today that its mRNA-1273 shot had an efficacy of 94.5% in the 30,000-patient COVE

News

Gilead and Novo plot next steps after trial data from NASH c...

Gilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked out in a mid-stage proof-of-concept study.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J begins trial of two-dose COVID-19 vaccine regimen

Johnson & Johnson has begun a second phase 3 trial of its potential COVID-19 vaccine, including sites in the UK, testing whether it works as a two-dose regimen.

Pfizer prepares to file COVID-19 shot after reaching safety ...

Lead Pharma signs $308m immune drug deal with Roche

Could an antidepressant be used to treat COVID-19?

UK eyes access deal as Moderna’s COVID-19 shot hits the mark

Gilead and Novo plot next steps after trial data from NASH c...

J&J begins trial of two-dose COVID-19 vaccine regimen

Why everyone should care about longevity, with Boyang Wang

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks